Alagene

Alagene
Israel's leading bio-foundry for synthetic biology innovation, spanning ideation to proof-of-concept.
About
What does Alagene do?
Alagene is a biotechnology service provider that manages the entire development lifecycle from R&D to commercialization. They offer tailored, high-quality solutions through a modular service model and open R&D approach, serving diverse sectors by transforming bold ideas into commercial success with speed and precision. Alagene acts as an extension of client teams, focusing on rapid, efficient, and economically viable project completion.
What is Alagene's revenue?
StartupHub estimates Alagene's annual revenue at $2.3M (range $1.3M to $3.7M, 64% confidence), based on comparable companies in the sector.
Where is Alagene headquartered?
Alagene is headquartered in Rehovot, Israel.
When was Alagene founded?
Alagene was founded in 2022.
What industry does Alagene operate in?
Alagene operates in Life Sciences, Computational Biology, Synthetic Biology, Biotech, Drug Discovery, Genomics.
How many employees does Alagene have?
Alagene has approximately 14 people on record.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Biotalent is a platform that streamlines biotech hiring by connecting qualified candidates with job opportunities and providing hiring teams with tools for efficient candidate review.
AI-powered platform accelerating biological research and drug discovery.
A healthcare and life sciences consulting firm leveraging AI and data analytics for strategic solutions.
Empowering Life Science Entrepreneurs for Innovative Healthcare Solutions.
An entrant is a company tagged Life Sciences whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.
